
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. is demonstrating significant progress in its clinical pipeline, particularly with product candidates RLY-4008 and RLY-2608, which have shown promising efficacy metrics, including an overall response rate (ORR) of 67% among patients with kinase mutations. The company’s innovative Dynamo platform enhances its capability to tackle difficult drug-protein targets, positioning it favorably within the precision oncology space. Furthermore, with anticipated cash reserves of $781 million to fully fund ongoing trials, Relay Therapeutics is well-positioned to advance its promising therapies while potentially increasing investor confidence in its long-term outlook.
Bears say
The financial outlook for Relay Therapeutics Inc is negatively impacted by a projected full-year 2025 net loss of $2.15 per share, indicating continued financial strain. Key risks include potential negative clinical data, setbacks in development timelines, and the possibility of failures in obtaining regulatory approvals, all of which could hinder the progress of their pipeline candidates. Additionally, the competitive landscape presents challenges, particularly concerning therapies that may exhibit safety limitations leading to reduced commercial success, along with the risk of dilution in the medium to long term.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares